1.
To assess patient choices with regard to adherence to long term therapy for the prevention of cardiovascular disease in Indigenous and non-Indigenous populations 2.
To understand, from the perspective of patients and providers, the factors that influence how well guidelines recommended therapy for cardiovascular disease in Indigenous and non-Indigenous populations are implemented
Key messages
1. This is an innovative study using a mixed methods approach to assess patient medications adherence that combines data on patients' stated preferences and their observed behaviour.
2.
The study will examine underlying reasons why adherence outcomes were (or were not) achieved within the context of a clinical trial of a cardiovascular polypill-based strategy and as such, serves as a process evaluation.
3. The findings will extrapolate the level of adherence observed in the trial to different 'real world' settings.
Strengths and limitations
1.
The strengths of the study are that it involves the innovative application of a preference study alongside a clinical trial, provides insights into how patients may respond to factors that influence adherence but not necessarily encounter in a clinical trial setting and addresses an important public health issue -namely treatment gaps in relation to cardiovascular disease prevention.
2.
The limitation is that it is a conducted in one country, Australia, and thus its generalisability may be limited by prevailing institutional arrangements. The RCT aims to assess whether provision of a polypill (containing low dose aspirin, a statin and two blood pressure lowering medicines) compared to usual cardiovascular medications improves adherence to indicated therapies and clinical outcomes among high-risk patients. Participants are being followed up for an average of 18 months. The main outcome of interest is adherence to indicated therapies defined as self-reported current use of antiplatelet, statin, and combination (≥ 2)
blood pressure lowering therapy. However, as there are substantial challenges in reliably measuring adherence, the study is powered to detect meaningful differences in the biological proxies of blood pressure and total cholesterol levels. Details on the study protocol are contained in the Australian and New Zealand Clinical Trials Registry (ACTRN12608000583347). (9) Analytical framework: Discrete Choice Experiment (DCE) as a tool for assessing therapeutic adherence within a process evaluation
The polypill strategy is not simply a pharmacological intervention -patients' adherence is likely to be influenced by their preferences and beliefs, the tangible and intangible costs incurred and the behaviour of providers. In this respect it can be defined as a complex intervention in which there are 'several interacting components' and in which providers and those receiving the intervention are expected to comply with behaviours that entail a significant degree of difficulty. (10) F o r p e e r r e v i e w o n l y
The inclusion of a process evaluation alongside a trial or outcome evaluation of a complex intervention has been posited as a means of understanding how and why an intervention might or might not have been effective. (10-13) Such evaluations utilise qualitative and quantitative methods and address specific issues about an intervention including how it is viewed by participants; how it was implemented; the distinction between its various components; the contextual factors that influence its effectiveness; its reach in terms of individuals/sites; and variation in effects across subgroups. (11) The ongoing prescription and consumption of the polypill in the real-world setting relies on patient and physician choices which in turn are influenced by the interplay of physician, patient, therapy, disease, and health-system characteristics. (14) In this context a process evaluation is needed to provide some indication of the generalisability of the results of the results of the trial to other settings. The findings will assist in translating the results into policy and practice.
We propose to undertake a discrete choice experiment, along with a series of qualitative interviews with patients, GPs and pharmacists, as a technique to address these issues. DCE is based on the notion, drawn from economic consumer theory, that individuals' demand for goods can be decomposed into preferences for specific 'attributes'. (15) For example, an individual's demand for a particular drug will be determined by attributes such as its known efficacy, side effects, cost and convenience of dosing. However, what we can observe in practice is choices between particular goods -or bundles of such attributes. Accordingly, DCEs involve the use of surveys in which respondents choose between alternative goods which vary in the level of their attributes. For instance, respondents are asked to choose between Drug Regimen A and Drug Regimen B based on the description of their attributes provided; assuming all else to be equal between the options (see Table below ). In this simplified example, the choice between Regimen A and Regimen B involves variation across 4 attributes: efficacy, side effects, cost and dosing. For a particular option (Regimen A or B) each of these attributes is set at certain 'levels' -here, the level of efficacy for both options are equal between A and B for the attributes efficacy and dosing. The choice is reduced simply to one of cost vs. of side-effects (e.g. a choice of B over A would imply that the respondent is willing to pay an extra $75 per month to avoid the side effect of nausea). In practice, a DCE survey would involve a series of such choices in which the level of each of the attributes is varied.
Insert figure 1 here
In designing a discrete choice experiment, the initial selection of attributes and their levels can be informed by a literature review or qualitative study. Typically DCE surveys conducted in health have involved choice sets containing 4-8 attributes. Given enough variation across all attributes through appropriate design, the approach enables, using multivariate models, estimates of a utility function in which each attribute and background characteristic of respondents represent separate parameters. Ultimately, through the estimation of a utility function, the approach enables:
• estimates of the individual effect of attributes of the products being compared (such as efficacy and cost of different drug regimens) and the background characteristics of the respondents (such as age, sex and risk factors) on consumers/or patients' choice of product (e.g. drug regimen A vs. B)
• estimates of the degree to which individuals are willing to trade-off one attribute for another.
For instance, how much are individuals willing to pay for reduction in side-effects from drug therapy?
• the forecasting of patient choices based on given attributes and respondent characteristics. For instance, for a given cost and demographic profile, what level of demand can we expect for a specific product?
Although initially developed in the marketing field, DCEs have been used extensively in health care. Given the potential cross cultural barriers that may exist with its deployment in the Kanyini GAP study population, extensive piloting will be needed in this study. (16) where non-adherence is viewed as deviance. (18) We are not aware of the use of DCEs as part of a process evaluation despite the increasing recognition of their value in assessing patient and consumer preferences in the health services research literature. Their role in process evaluation would be based on their capacity to explain the motivation and behaviour of agents in the course of an intervention -complex or otherwise.
Furthermore the use of DCE in conjunction with a clinical trial provides an opportunity for combining two sources of data. This represents an important methodological development as although the outcomes of a clinical trial reflect the actual behaviour of participants (revealed preference) such behaviour is constrained by the parameters in which the study takes place. These constraints on behaviour and the attributes that may influence such behaviour that are imposed by the research design limit the ability to extrapolate to circumstances which may differ from those existing within the study. Thus whilst clinical trial data involves comparison of two fixed options, 'stated preference' methods such as DCE have the flexibility to allow for the construction and testing of hypothetical scenarios. With appropriate scaling, the data from such studies can be combined to provide more robust model estimates and furthermore allow consideration of a wider range of factors that modify adherence behaviour than stated or revealed preference data alone. (19, 20) The aims of this study are:
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METHODS/DESIGN
This study comprises inter-related two components: A) a DCE of patients to determine the factors that influence adherence to therapy and; B) a qualitative study of patients, general practitioners and pharmacists.
The DCE will be carried out by interview administered survey by a study nurse at the end of each final follow-up visit in the Kanyini GAP trial. This allows us to conduct the survey as a face to face interview (as opposed to the usual postal self-administered or telephone method). The advantages of this strategy are that it allows the interviewer to better explain the tasks involved in the survey and it capitalises on access to the participant afforded by the trial thereby minimising both the risk of nonresponse and the costs associated with administration. The questionnaire will undergo extensive piloting across the study sites on patients not involved in the trial -this will inform its design, wording and formatting.
DCE
Establishing relevant attributes and levels.
An initial set of attributes will be established through a review of the literature on therapeutic adherence and cardiovascular disease. The aim of this review is to capture, for potential inclusion as attributes in the DCE survey, the most important factors likely to influence individuals' adherence behaviour. Specifically the task here will be to: 1) establish a feasible set of attributes for inclusion in the survey (usually up to 8) and; 2) establish the levels at which these attributes are set (e.g. the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y range of cost to the patient might be set from zero to $100 per month) based on their feasibility in practice.
Questionnaire design
The appropriate combination of attributes and levels to be posed in the DCE survey will be based on consideration of both the statistical properties of Efficient Choice (EC) design and pragmatic judgments about the plausibility of the choice sets offered. CI Rose is a recognized leader in research into such design principles and will lead this aspect of the study.
It is rarely feasible or efficient to test every combination of attribute and attribute levels through a 'full factorial design' and thus an EC approach can be deployed to establish a 'fractional factorial design' that links statistical efficiency to the likely econometric model that is to be estimated from discrete choice data. Design software package NGene 1.0 will be deployed to generate such a design. The principle used is the minimization of the correlation in the data for estimation purposes so that standard errors on parameter estimates are ultimately minimized. (21, 22 ) Such a design makes use of prior information about such estimates which can be derived in this study from data obtained from the initial piloting as described above.
In addition the characteristics of the choices posed will also be influenced by judgement about the real life feasibility of the specific combinations e.g. if the number of pills taken per day and copayment are posed as attributes, then for any choice, it is highly unrealistic that the co-payment level will be set higher when number of pills per day is lower. Thus the design will be restricted from allowing such combinations.
From such principles, a survey will be designed in which a series of choices will be posed between two unlabelled options representing alternative treatment regimens. These will vary by attributes Finally a joint model combining revealed preference (observed adherence in the clinical trial) and stated preference data (DCE) will be estimated. Such estimation needs to take into account potential differences in noise levels in the two datasets through error variance scaling. Once completed, the parameter estimates on the rescaled data can be directly compared across datasets and the pooled data can be analysed through MMNL as above. (20) The estimated models will be subject to usual diagnostics including goodness of fit and the level of internal prediction.
The analysis will address Aim 1 of the study and will specifically provide:
Estimates of the marginal effect (importance) of each attribute on overall choice, e.g. if a cost attribute is presented in the DCE, the analysis will provide an estimate of the relative effect of cost on adherence to therapy.
Estimates of marginal rates of substitution between attributes, giving an indication of the extent to which respondents are prepared to trade-off one attribute for another e.g. if cost
and side effects are offered as attributes in the survey, the marginal rate of substitution between these will reflect the additional cost patients may be willing to accept as a trade-off for avoiding certain side effects.
An indication of the predicted values or 'market shares' associated with different parameter levels within the estimated utility functions. This allows forecasting of, for instance, the level of adherence that could be expected given a fixed set of attributes (e.g. cost,
effectiveness and side-effects) and, contextual and socio-demographic characteristics. This forecast can be used inform policy directed at altering attribute levels to enhance adherence and be estimated separately across different contexts and population sub-groups.
Qualitative study
A series of interviews with patients and providers involved in the Kanyini GAP RCT will be carried out to provide in-depth understanding of the reasons for adherence/ non-adherence to therapy for cardiovascular disease prevention -as observed within the trial and in practice, as would be the case beyond the trial setting. Recruitment of both providers and patients for interview will be purposive, to maximise variation on criteria such as location, practice size and degree of participation (for providers) and location, gender, age and outcomes (for patients). Background and adherence data obtained from the trial and DCE will be used to inform this recruitment. Sampling will continue until no new themes or categories emerge from the data (so-called 'thematic saturation'). We anticipate from previous experience the need to conduct around 20 GP interviews, 10 pharmacist interviews and 40 patient interviews (20 Indigenous and 20 non-Indigenous) -and this is reflected in our budget estimates. Interviews will be scheduled to take place after the DCE. The interviews will be conducted face to face by a project officer, with an Aboriginal project officer responsible for conducting the interviews with Aboriginal participants.
Provider interviews
Participating GPs and pharmacists will be administered an in-depth interview to explore:
• their views on the advantages, disadvantages, acceptability and applicability of the polypill strategy relative to current practices
• what variations were there across patient groups in terms of experience and performance of the polypill strategy relative to current practices
• particular incidents when prescription of the polypill proved helpful for themselves and/or the patient, and incidents when it was not advantageous
• how might their behaviour within the trial be modified outside the study setting
• what characteristics of the study setting mean that behaviour observed within it may not be reflective of provider behaviour in practice
• broader questions about their perceptions regarding the factors that either hinder or facilitate patient adherence to either the polypill strategy or current prescribed treatments in practice
• suggestions for interventions or policies to improve adherence 
Patient interviews
Patient interviews which will be conducted in patients in both treatment and control groups will be used to explore in greater depth:
• their views on the benefits, disadvantages and acceptability of their current treatment (polypill or usual care)
• reports on specific instances where changes occurred to their usual adherence behaviour and the circumstances surrounding these
• the factors that hinder or facilitate their attitude toward adherence to therapy within the trial
• the factors that in practice would modify patients' adherence behaviour from that exhibited in the trial
Analysis of the interview data will be thematic, and NVivo 8 will be used to assist with the management of the data. Coding will be carried out inductively based on the themes that emerge from the interviews. (27) The analysis will be undertaken by members of the study team (TU, DP and PSPs 1 and 2) so that themes can be cross checked. In accordance with normal qualitative research practice, this will occur concurrently with the interviews and thus themes will be assessed continually in light of additional data. Such data will be used as a means of exploring in greater depth the preferences observed in both the trial and in the DCE and ultimately provide important narratives on the experiences and perspectives of individuals with regard to adherence behaviour.
This will form the basis for a set of standalone research findings (Aim 2).
Reporting
In addition to usual scientific forums the findings will be reported back to the communities involved in the studies through site-specific reports and oral presentations. 
DISCUSSION
Non-adherence represents a major reason for the significant health inequalities that exist for chronic illnesses in Australia. CVD represents the single largest public health burden for Australia, and major challenges in providing preventive therapy of proven effectiveness remain. Currently a trial is underway assessing a fixed-dose combination therapy to improve adherence to therapy. This study will provide an opportunity to value-add to this trial by examining the underlying reasons why providers and patients may or may not adhere to recommended guidelines; taking into account the role of providers, tangible and intangible costs and the preferences of patients. The findings of the trial will thus be extended and quantified using a discrete choice experiment to model the impact of both patient and treatment attributes on adherence. Methodologically, this use of DCE will represent a significant development in RCT process evaluation that will generate deep insights into the preferences and behaviour of individuals and allow extrapolation to settings that differ from those in which the trial was conducted. The study will enable policy makers to model the cost and other attributes of treatment to achieve targeted levels of adherence, understand better the tradeoffs in doing so and ultimately deliver more effectively proven long term strategies for the prevention and management of cardiovascular disease and other chronic illnesses. Tracey Laba is funded by an NHMRC Scholarship and NHMRC Capacity Building Grant (571372).
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Key messages
2.
Strengths and limitations

1.
2.
The limitation is that it is a conducted in one country, Australia, and thus its generalisability may be limited by prevailing institutional arrangements. 
BACKGROUND Current gap between guidelines and practice
Despite the strong evidence-base for therapies effective at reducing cardiovascular disease (CVD) morbidity and mortality, and incorporation of this evidence in therapeutic guidelines, a substantial gap between recommended treatment and clinical practice exists.
The reasons for the current treatment gaps are complex but in addition to poor dissemination and uptake of guidelines other factors include: low continuation rates by patients, inequities in health services, and resistance (by both doctors and patients) to the cost, complexity and stigmatisation of prescribing four or more cardiovascular medications. Low medication adherence rates are a well- 
Existing study: A RCT of a polypill based strategy to improve implementation of guidelines for cardiovascular disease prevention
The use of fixed-dose combination therapy to prevent CVD has generated debate since Wald and Law advocated the widespread use of a "polypill" containing aspirin, a statin, three low-dose blood pressure-lowering drugs and folic acid for the prevention of CVD events.(8) It has been proposed that fixed-dose combination pills may improve adherence by reducing the number and complexity of dosing regimens for doctors and patients, and improving access to treatment by reducing costs. 
Analytical framework: Discrete Choice Experiment (DCE) as a tool for assessing therapeutic adherence within a process evaluation
The polypill strategy is not simply a pharmacological intervention -patients' adherence is likely to be influenced by their preferences and beliefs, the tangible and intangible costs incurred and the behaviour of providers. In this respect it can be defined as a complex intervention in which there are 'several interacting components' and in which providers and those receiving the intervention are expected to comply with behaviours that entail a significant degree of difficulty.(10) The inclusion of a process evaluation alongside a trial or outcome evaluation of a complex intervention has been posited as a means of understanding how and why an intervention might or might not have been effective. (10-13) Such evaluations utilise qualitative and quantitative methods and address specific issues about an intervention including how it is viewed by participants; how it was implemented; the distinction between its various components; the contextual factors that influence its effectiveness; its reach in terms of individuals/sites; and variation in effects across subgroups. (11) The ongoing prescription and consumption of the polypill in the real-world setting relies on patient and physician choices which in turn are influenced by the interplay of physician, patient, therapy, disease, and health-system characteristics. (14) In this context a process evaluation is needed to provide some indication of the generalisability of the results of the results of the trial to other settings. The findings will assist in translating the results into policy and practice.
We propose to undertake a discrete choice experiment, along with a series of qualitative interviews with patients, GPs and pharmacists, as a technique to address these issues. DCE is based on the notion, drawn from economic consumer theory, that individuals' demand for goods can be decomposed into preferences for specific 'attributes'. (15) Table below ). In this simplified example, the choice between Regimen A and Regimen B involves variation across 4 attributes: efficacy, side effects, cost and dosing. For a particular option (Regimen A or B) each of these attributes is set at certain 'levels' -here, the level of efficacy for both options are equal between A and B for the attributes efficacy and dosing. The choice is 
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Although initially developed in the marketing field, DCEs have been used extensively in health care. Given the potential cross cultural barriers that may exist with its deployment in the Kanyini GAP study population, extensive piloting will be needed in this study. (16) The rationale for the use of DCEs within this process evaluation is the view that adherence is in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
METHODS/DESIGN
This study comprises two inter-related components: A) a DCE of patients to determine the factors that influence adherence to therapy and; B) a qualitative study of patients, general practitioners and pharmacists.
DCE
Establishing relevant attributes and levels.
An initial set of attributes will be established through a review of the literature on therapeutic adherence and cardiovascular disease. The aim of this review is to capture, for potential inclusion as attributes in the DCE survey, the most important factors likely to influence individuals' adherence behaviour. Specifically the task here will be to: 1) establish a feasible set of attributes for inclusion in the survey (usually up to 8) and; 2) establish the levels at which these attributes are set (e.g. the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 range of cost to the patient might be set from zero to $100 per month) based on their feasibility in practice.
Questionnaire design
From such principles, a survey will be designed in which a series of choices will be posed between two unlabelled options representing alternative treatment regimens. These will vary by attributes 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y that potentially influence patient adherence to treatment such as cost, dosing, whether administered as a polypill or not, side-effects and perceived effectiveness.
DCE survey
The sites for the DCE will be those involved in the Kanyini GAP RCT. Aboriginal participants are being mainly recruited from health service partners comprising Aboriginal community controlled health services across Australia. The surveys of Aboriginal participants will be carried out specifically by an Aboriginal project officer. Non-Aboriginal participants will be recruited predominantly from general practices in NSW, Victoria and Queensland. (9) Centres have been selected on the basis of interest in participating in the study, practice size and location, and clinical research experience. 60% of individual participants will be Indigenous. We anticipate that taking into account attrition of 10% from loss to follow-up and death, 900 of the original 1000 participants will be eligible to participate in the survey at final follow-up. One significant advantage of conducting the DCE within the clinical trial is in the potential to access large numbers of well-motivated respondents. As such we anticipate that the response rate to the survey will be higher than those conventionally encountered in DCE studies which are generally conducted in a general population setting -previous studies conducted in clinical settings have yielded response rates of between 90-100%.(23) Assuming a refusal rate of 10%, we would expect 810 respondents. Because each respondent yields multiple observations based on the number of discrete choice questions they answer and that most DCE studies in health care have contained 9-16 choices,(23) we would thus expect to obtain between 7,290 -12,960 observations. In our experience previous comparable surveys in health care have been successfully carried out with the number of participants generally well below 800. A post hoc analysis of the Kanyini GAP RCT will be undertaken to provide an initial assessment of the factors influencing adherence to treatment. As we are interested in the role not simply of the intervention but potentially a broader set of covariates in influencing this outcome -and because randomisation controls for such covariates -the analysis will be carried out on a pooled dataset of subjects in both arms of the trial. The modeling strategy will entail a multivariate logistic analysis in which adherence will be assessed as a function of individuals' background characteristics (such as age, sex, disease history, Aborginality), attributes of intervention (e.g. copayment and dosing), Finally a joint model combining revealed preference (observed adherence in the clinical trial) and stated preference data (DCE) will be estimated. Such estimation needs to take into account potential differences in noise levels in the two datasets through error variance scaling. Once completed, the parameter estimates on the rescaled data can be directly compared across datasets and the pooled data can be analysed through MMNL as above. (20) The estimated models will be subject to usual diagnostics including goodness of fit and the level of internal prediction. Analysis of these data will be undertaken after all the interviews have been conducted.
Analysis and interpretation
An indication of the predicted values or 'market shares' associated with different parameter levels within the estimated utility functions. This allows forecasting of, for instance, the level of adherence that could be expected given a fixed set of attributes (e.g. cost, effectiveness and side-effects) and, contextual and socio-demographic characteristics. This forecast can be used inform policy directed at altering attribute levels to enhance adherence and be estimated separately across different contexts and population sub-groups. Qualitative study A series of interviews with patients and providers involved in the Kanyini GAP RCT will be carried out to provide in-depth understanding of the reasons for adherence/ non-adherence to therapy for cardiovascular disease prevention -as observed within the trial and in practice, as would be the case beyond the trial setting. Recruitment of both providers and patients for interview will be purposive, to maximise variation on criteria such as location, practice size and degree of participation (for providers) and location, gender, age and outcomes (for patients). Background and adherence data obtained from the trial and DCE will be used to inform this recruitment. Sampling will continue until no new themes or categories emerge from the data (so-called 'thematic saturation'). We anticipate from previous experience the need to conduct around 20 GP interviews, 10 pharmacist interviews and 40 patient interviews (20 Indigenous and 20 non-Indigenous) -and this is reflected in our budget estimates. Interviews will be scheduled to take place after the DCE. The interviews will be conducted face to face by a project officer, with an Aboriginal project officer responsible for conducting the interviews with Aboriginal participants.
Provider interviews
• what characteristics of the study setting mean that behaviour observed within it may not be reflective of provider behaviour in practice • broader questions about their perceptions regarding the factors that either hinder or facilitate patient adherence to either the polypill strategy or current prescribed treatments in practice
• suggestions for interventions or policies to improve adherence
Patient interviews
Analysis of the interview data will be thematic, and NVivo 8 will be used to assist with the management of the data. Coding will be carried out inductively based on the themes that emerge from the interviews. (27) The analysis will be undertaken by members of the study team (TU, DP and PSPs 1 and 2) so that themes can be cross checked. In accordance with normal qualitative research practice, analysis will occur concurrently with the interviews and thus themes will be assessed continually in light of additional data. Such data will be used as a means of exploring in greater depth the preferences observed in both the trial and in the DCE and ultimately provide important narratives on the experiences and perspectives of individuals with regard to adherence behaviour. This will form the basis for a set of standalone research findings (Aim 2). Participants in the trial will be provided an information sheet about the study and asked to sign and date a consent form. A copy will be given to the participant and the original retained at each site attached to the medical records of the participant.
Consent
Data management and handling
Data management will be carried out at the George Institute. The recordings and transcripts from the qualitative interviews and completed DCE surveys will be securely stored with data files password protected and accessible only to the study team. These records will be destroyed after 15
years.
Reporting
DISCUSSION
Non-adherence represents a major reason for the significant health inequalities that exist for chronic illnesses in Australia. CVD represents the single largest public health burden for Australia, and major challenges in providing preventive therapy of proven effectiveness remain. Currently a trial is underway assessing a fixed-dose combination therapy to improve adherence to therapy. This study will provide an opportunity to value-add to this trial by examining the underlying reasons why providers and patients may or may not adhere to recommended guidelines; taking into account the role of providers, tangible and intangible costs and the preferences of patients. The findings of the trial will thus be extended and quantified using a discrete choice experiment to model the impact of both patient and treatment attributes on adherence. Methodologically, this use of DCE will represent a significant development in RCT process evaluation that will generate deep insights into the preferences and behaviour of individuals and allow extrapolation to settings that differ from those in which the trial was conducted. The study will enable policy makers to model the cost and other attributes of treatment to achieve targeted levels of adherence, understand better the tradeoffs in doing so and ultimately deliver more effectively proven long term strategies for the prevention and management of cardiovascular disease and other chronic illnesses. The funders will have no role in the conduct of the study, nor in publication decisions. These will be undertaken independently by the study team (authors).
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